A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer

E. S. Ratner, F. K. Keane, R. Lindner, R. A. Tassi, T. Paranjape, M. Glasgow, S. Nallur, Y. Deng, L. Lu, L. Steele, S. Sand, R. U. Muller, E. Bignotti, S. Bellone, M. Boeke, X. Yao, S. Pecorelli, A. Ravaggi, D. Katsaros, D. ZeltermanM. C. Cristea, H. Yu, T. J. Rutherford, J. N. Weitzel, S. L. Neuhausen, P. E. Schwartz, F. J. Slack, A. D. Santin, J. B. Weidhaas

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Fingerprint

Dive into the research topics of 'A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences